Overview

Support

Web-Ordering

Overview

Support

Web-Ordering

Contrast Media

Behind every image is a patient. We provide a comprehensive portfolio of contrast media to help meet patient and procedural needs across imaging modalities.

Adverse events reporting

Adverse events should be reported.
Reporting forms and information can be found at https://www.yellowcard.mhra.gov.uk/ .
Adverse events should also be reported to GE HealthCare at
gpv.drugsafety@gehealthcare.com

100M+

doses currently produced globally every year¹

150M+

patient doses planned for production by 2031²

4cGMP

accredited contrast media production facilities globally

~$450 million

invested between 2020 and 2025, to expand our production capacity

CONTRAST MEDIA

GE HealthCare has a distinguished heritage of contrast media development, offering a comprehensive product range across modalities, with a range of concentrations and innovative packaging choices.

Beyond the scan

Securing future supply of contrast media.

Products

Omnipaque

Visipaque

Clariscan

Rapiscan

Gadobutrol

Omnipaque
Visipaque
Clariscan
rapiscan
gadobutrol

Please click here for OMNIPAQUE™ (iohexol) Prescribing Information.
Please click here for VISIPAQUE™ (iodixanol) Prescribing Information.
Please click here for Clariscan™ (gadoteric acid) Prescribing Information.
Please click here for Rapiscan™ (regadenoson) Prescribing Information.
Please click here for Gadobutrol Prescribing Information.

INNOVATIVE PACKAGING

+PLUSPAK 100% recyclable packaging

Our +PLUS PAK packaging, used for contrast media product, is 100% recyclable. A life-cycle analysis showed that our polypropylene bottles, compared to glass, have a 59% lower environmental impact, and requires 45% less cumulative energy. Our +PLUS PAK bottles, also require less secondary packaging, helping reduce carbon footprint.³

References

1. GE HealthCare -Data on file. Contrast Media Demand and Investment - November 2025
2. GE HealthCare- Data on file. PDx Investment to Increase Production Capacity March 2026
3. Dhaliwal et al. Int J Life Cycle Assess 2014: 19: 1965-73

cGMP: Current Good Manufacturing Practice

Thank you!

We received your request for assistance.

A GE Healthcare specialist will be reaching out shortly.

Something went wrong

We will check and get back.

Try Again

JB04728UK